Nutriband CEO Discusses AVERSA Technology’s Role in Addressing Opioid Crisis on Podcast

Nutriband Inc. CEO and Co-Founder Gareth Sheridan recently appeared on the Jack Neel Podcast to discuss the ongoing opioid crisis and the company’s AVERSA abuse-deterrent transdermal technology. The discussion centered on how this technology aims to address critical public health concerns surrounding prescription drug misuse.

The AVERSA technology is specifically designed to reduce misuse, diversion, and accidental exposure of high-risk drugs such as fentanyl while maintaining appropriate patient access to necessary medications. This balance between preventing abuse and ensuring therapeutic availability represents a significant development in pharmaceutical safety measures. The technology is supported by a broad global patent portfolio, providing intellectual property protection for Nutriband’s innovation.

Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products, with their lead product being an abuse-deterrent fentanyl patch incorporating the AVERSA technology. According to company information, this technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company maintains a website at https://www.nutriband.com where additional information about their products and technology is available.

The broader implications of this technology extend beyond individual patient safety to address systemic issues in prescription drug management. By creating physical barriers to misuse through transdermal delivery systems, AVERSA technology represents a practical approach to reducing opioid-related harm while preserving legitimate medical use. This development comes at a time when communities nationwide continue grappling with the devastating effects of opioid addiction and overdose deaths.

For investors and stakeholders following Nutriband’s progress, the latest news and updates relating to the company are available through their newsroom at https://ibn.fm/NTRB. The original press release announcing the podcast appearance can be viewed at https://ibn.fm/fSUKj. The podcast discussion provides insight into how pharmaceutical innovation can contribute to solving complex public health challenges while maintaining ethical drug development practices.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Nutriband CEO Discusses AVERSA Technology’s Role in Addressing Opioid Crisis on Podcast.

The post Nutriband CEO Discusses AVERSA Technology’s Role in Addressing Opioid Crisis on Podcast appeared first on citybuzz.